The Anxiety Disorders: A Review

  • Robert O. Pasnau
  • Alexander Bystritsky


The preceding quote was chosen by Dr Louis Jolyon West in his introduction to his chapter on post-traumatic anxiety in 1984.1 In that chapter, he reviews an area of his own personal interest and research dating back to the Korean Conflict in the 1950s. His studies on anxiety and its vicissitudes have been extended in recent years to focus on victims of torture, subjects of terrorism, and those abused by charismatic cults.


Anxiety Disorder Generalize Anxiety Disorder Chronic Fatigue Syndrome Social Phobia Panic Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    West LJ, Coburn K. Post-traumatic anxiety. In: Pasnau RO, ed. The Diagnosis and Treatment of Anxiety Disorders. Washington, DC: American Psychiatric Press; 1984:81–113.Google Scholar
  2. 2.
    NIMH epidemiologic catchment area program. Arch Gen Psychiatry. 1984;41:931–1012.Google Scholar
  3. 3.
    Regier DA, Boyd JH, Burke JD, et al. One-month prevalence of mental disorders in the United States. Arch Gen Psychiatry. 1988;45:977–986.PubMedGoogle Scholar
  4. 4.
    Pasnau RO, Bystritsky A. An overview of anxiety disorders. Bull Menninger Clin. 1990;54:157–170.PubMedGoogle Scholar
  5. 5.
    McNair DM. Psychosocial and Economic Issues in Benzodiazepine Use Presented at meeting entitled benzodiazepines: Therapeutic, biologic, and psychosocial issues; September 30–October 1,1988; Boston.Google Scholar
  6. 6.
    Liebowitz, MR, Fryer AJ, Gorman J, Klein DF. Recent developments in the understanding and pharmacotherapy of panic attacks. Psychopharmacol Bull. 1986;22:792–796.PubMedGoogle Scholar
  7. 7.
    Lydiard RB, Roy-Byrne PP, Ballenger JC. Recent advances in the psychopharmacological treatment of anxiety disorders. Hosp Community Psychiatry. 1988;39:1157–1165.PubMedGoogle Scholar
  8. 8.
    Taylor CB, Arnow B. The Nature and Treatment of Anxiety Disorders. London: Collier-Macmillan; 1988.Google Scholar
  9. 9.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Third Edition—Revised. Washington, DC: American Psychiatric Association; 1987.Google Scholar
  10. 10.
    Fogelson DL, Bystritsky A, Sussman N. Inter-relationship between major depression and the anxiety disorders. Clinical relevance. Psychiatr ann. 1987;18:158–167.Google Scholar
  11. 11.
    Weissman MM, Klerman GL, Markowitz JS, Ouellette R. Suicidal ideation and suicide attempts in panic disorder and attacks. N Engl J Med. 1989;321:1209–1214.PubMedCrossRefGoogle Scholar
  12. 12.
    Di Nardo PA, O’Brien GT, Barlow DR, Waddele MJ, Blanchard EB. Reliability of DSMIII anxiety disorder categories using a new structured interview. Arch Gen Psychiatry. 1983; 40:1070–1074.PubMedGoogle Scholar
  13. 13.
    Taylor CB, Sheikh J, Agras WS, Roth WT. Ambulatory heart rate changes in patients with panic attacks. Am J Psychiatry. 1986;143:478–482.PubMedGoogle Scholar
  14. 14.
    Margraf J, Ehlers A, Roth WT. Sodium lactate infusions and panic attacks: a review and critique. Psychopharmacol Bull. 1986;48:23–51.Google Scholar
  15. 15.
    Gorman JM, Liebowitz MR, Fyer AJ, Klein DF. Possible respiratory abnormalities in panic disorder. Psychopharmacol Bull. 1986;22:797–801.PubMedGoogle Scholar
  16. 16.
    Van den Hout MA, Greiz E. Panic symptoms after inhalation of carbon dioxide. Br J Psychiatry. 1984;144:503–507.PubMedCrossRefGoogle Scholar
  17. 17.
    Clark DM. A cognitive approach to panic. Behav Res Ther. 1986;24:461–470.PubMedCrossRefGoogle Scholar
  18. 18.
    Beck AT, Emery G. Anxiety Disorders and Phobias: A Cognitive Perspective. New York: Basic Books; 1985.Google Scholar
  19. 19.
    Veith RC. Sympathetic nervous system function in depression and panic. In: Brown M, Rivier C, Koob G, ed. Neurobiology and Neuroendocrinology of Stress. New York: Marcel Dekker. In press.Google Scholar
  20. 20.
    Charney DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry. 1984;41:751–763.PubMedGoogle Scholar
  21. 21.
    Pitts FN, Allen RE. Beta-adrenergic blockage in treatment of anxiety. In: Mathew RJ, ed. Biology of Anxiety. New York: Brunner & Mazel; 1980.Google Scholar
  22. 22.
    Charney DS, Menkes DB, Phil M, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment. Arch Gen Psychiatry. 1981;38:1160–1180.PubMedGoogle Scholar
  23. 23.
    Hoen-Saric R. Neurotransmitter in anxiety. Arch Gen Psychiatry. 1982;39:735–743.Google Scholar
  24. 24.
    Dorow R. Beta-carboline causes anxiety in man. Presented at 13th Collequim International Neuro-psychopharmacologic Congress; June 1982; Jerusalem.Google Scholar
  25. 25.
    Van Praag HM, Kahn R, Asnis GM, Lemus CZ, Brown SL. Therapeutic indications for serotonin—potentiating compounds: a hypothesis. Biol Psychiatry. 1987;22:205–212.PubMedCrossRefGoogle Scholar
  26. 26.
    Kahn RS, Van Praag HM, Wetzler S, Asnis G, Barr G. Serotonin and anxiety revisited. Biol Psychiatry. 1988;23:189–208.PubMedCrossRefGoogle Scholar
  27. 27.
    Kahn RS, Westenberg HGM. L-5-hydroxytryptophan in the treatment of anxiety disorders. J Affective Disord. 1985;8:197–200.CrossRefGoogle Scholar
  28. 28.
    Den Boer JA, Westenberg HGM, Kamerbeek WDJ, Verhoeven WMA, Kahn RS. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol. 1987; 2:21–32.CrossRefGoogle Scholar
  29. 29.
    Kahn RS, Wetzler S, VanPraag HM, Amis GM. Behavioral indication of serotonin receptor hypersensitivity in patients with panic disorders. Psychiatry Res. 1988;25:101–107.PubMedCrossRefGoogle Scholar
  30. 30.
    Liebowitz MR, Fryer AJ, Gorman JM, et al. Lactate provocation of panic attacks. I: clinical and behavioral findings. Arch Gen Psychiatry. 1986;41:764–770.Google Scholar
  31. 31.
    Clark DM, Hemsley DR. The effects of hyperventilation: individual variability and its relation to personality. J Behav Ther Exp Psychiatry. 1982;13:41–47.PubMedCrossRefGoogle Scholar
  32. 32.
    Reiman EM, Raichle ME, Robins E, et al. Application of positron emission tomography to the anxiety and panic disorders. Am J Psychiatry. 1986;143:469–477.PubMedGoogle Scholar
  33. 33.
    Charney DS, Heninger GR, Jatlow PI. Increased angiogenic effects of caffeine in panic patients. Arch Gen Psychiatry. 1985;42:233–243.PubMedGoogle Scholar
  34. 34.
    Margraf J, Ehlers A, Roth WT. Panic attacks: theoretical models and empirical evidence. In: Hand I, Wittchen HU, eds. Panic and Phobias. Berlin: Springer-Verlag; 1986.Google Scholar
  35. 35.
    Harris EL, Noyes R Jr, Crowe RR, et al. Family study of agoraphobia. Arch Gen Psychiatry. 1983;40:1061–1064.PubMedGoogle Scholar
  36. 36.
    Torgersen S. Genetic factors in anxiety disorder. Arch Gen Psychiatry. 1983;40:1085–1089.PubMedGoogle Scholar
  37. 37.
    Surman OS, Sheehan DV, Fuller TC, et al. Panic disorder in genotypic HLA identical sibling pairs. Am J Psychiatry. 1983;140:237–238.PubMedGoogle Scholar
  38. 38.
    Baxter LR, Phelps ME, Massiotta TC, et al. Local cerebral glucose metabolic rates in obsessive-compulsive disorders. Arch Gen Psychiatry. 1987;44:211–218.PubMedGoogle Scholar
  39. 39.
    Hollander E, Fay M, Cohen B, Campeas R. Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. Am J Psychiatry. 1988;145:1015–1017.PubMedGoogle Scholar
  40. 40.
    Birkhimer LJ, DeVane CL, Muniz CE. Posttraumatic stress disorder: characterizations and pharmacological response in the veteran population. Compr Psychiatry. 1985;26:309–310.CrossRefGoogle Scholar
  41. 41.
    Rainy JM, Aleem A, Ortiz A, et al. A laboratory method for the induction of flashbacks. Am J Psychiatry. 1987;144:1317–1319.Google Scholar
  42. 42.
    Ewing JA. Detecting alcoholism: the CAGE questionnaire. JAMA. 1984;252:1905–1907.PubMedCrossRefGoogle Scholar
  43. 43.
    Roy-Byrne PP, Uhde TW. Exogenous factors in panic disorders: clinical and research implication. J Clin Psychiatry. 1988;49:56–61.PubMedGoogle Scholar
  44. 44.
    Rako SM, Mazer HE, eds. Semrad: The Heart of a Therapist. New York: Jason Aronson; 1980.Google Scholar
  45. 45.
    Gelder M. Behavior therapy for neurotic disorders. Behav Modif. 1979;3:469–495.CrossRefGoogle Scholar
  46. 46.
    Heinrich RL. Behavioral approaches to the evaluation and treatment of anxiety disorders. In: Pasnau RO, ed. Diagnosis and Treatment of Anxiety Disorders. Washington, DC: American Psychiatric Press; 1984.Google Scholar
  47. 47.
    Cobb JP. The non-pharmacological management of anxiety. Br J Clin Pract Symp Suppl. 1985;58:42–47.Google Scholar
  48. 48.
    Foa EB, Steketee GS, Ozarow BJ. Behavior therapy with obsessive-compulsives: from theory to treatment. In: Mavissakalian M, ed. Obsessive-Compulsive Disorder: Psychological and Pharmacological Treatment. New York: Plenum; 1985:41–129.Google Scholar
  49. 49.
    Orne MT. Task Force Report 19. Biofeedback. Washington, DC: American Psychiatric Asso ciation; 1980.Google Scholar
  50. 50.
    Barlow DM, O’Brien GT, Last OG. Couples treatment of agoraphobia. Behav Ther. 1982; 15:41–58.CrossRefGoogle Scholar
  51. 51.
    Ballenger JC, Burrows GD, DuPont RL Jr, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: efficacy in short-term treatment. Arch Gen Psychiatry. 1988;45:413–422.PubMedGoogle Scholar
  52. 52.
    Alprazolam for panic disorder. Med Lett Drugs Ther. 1991;33:30–31.Google Scholar
  53. 53.
    Kales A. Benzodiazepine hypnotics and insomnia. Hosp Pract [Off]. 1990;25:7–22.Google Scholar
  54. 54.
    Browne JL, Hauge KJ. A review of alprazolam withdrawal. Drug Intell Clin Pharm. 1986;20:837–841.PubMedGoogle Scholar
  55. 55.
    Pecknold JC, Swinson RP, Kuch K, Lewis CP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Arch Gen Psychiatry. 1988;45:429–436.PubMedGoogle Scholar
  56. 56.
    Tesar GE, Rosenbaum JF, Pollack MH, et al. Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind placebo-controlled trial. J Clin Psychiatry. 1987;48:16–19.PubMedGoogle Scholar
  57. 57.
    Mavissakalian M, Mechelson L. Two year follow-up of exposure and imipramine treatment of agoraphobia. Am J Psychiatry. 1986;43:1106–1112.Google Scholar
  58. 58.
    Jenike MA, Baer L, Minichiello A. Obsessive-Compulsive Disorders: Theory and Management. Littleton, Mass: PSG Publishing; 1986.Google Scholar
  59. 59.
    Gorman JM, Gorman LK. Drug treatment of social phobia. Affective Dis. 1987;13:183–192.CrossRefGoogle Scholar
  60. 60.
    Shehi M, Patterson WM. Treatment of panic attacks with alprazolam and propanolol. Am J Psychiatry. 1984;141:900–901.PubMedGoogle Scholar
  61. 61.
    Freedman AM. Psychopharmacology and psychotherapy in the treatment of anxiety. Curr Psychiatr Ther. 1986;25:101–118.Google Scholar
  62. 62.
    The Collaberative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorders. Arch Gen Psychiatry. 1991;48:730–738.Google Scholar
  63. 63.
    Gorman JM, Liebowitz MR, Fyer AJ, et al. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol. 1987;7:329–332.PubMedCrossRefGoogle Scholar
  64. 64.
    Kahn RS, Westenberg HGM, Verhoeven WMA, Gispende Wied CC, Kamerbeek WDJ. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Internat Clin Psychopharmacol. 1987;2:33–45.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1992

Authors and Affiliations

  • Robert O. Pasnau
  • Alexander Bystritsky

There are no affiliations available

Personalised recommendations